Brisdelle vs Veozah: Which Nonhormonal Hot Flash Medication Fits You?
Educational research, not medical advice, and not medically reviewed by a clinician. The HRT Index is reader-supported. We may earn a commission when you use some provider links, but our recommendations are based on verification and fit — not payout.
The short answer
The Brisdelle vs Veozah decision comes down to three things: how much each lowered hot flashes, whether you can handle Veozah’s liver-test schedule, and the tamoxifen catch that quietly steers some women away from Brisdelle. There’s no universal winner. Veozah cut hot flashes more in its own studies, but costs far more and carries a serious liver warning. Brisdelle is usually much cheaper, but it isn’t right for everyone.
Brisdelle (low-dose paroxetine) and Veozah (fezolinetant) are two FDA-approved nonhormonal prescription pills for moderate-to-severe menopause hot flashes. In its own trials, Veozah lowered daily hot flashes more than Brisdelle did in its trials, but it carries a boxed warning for rare, serious liver injury and requires blood-test monitoring. Brisdelle is usually much cheaper, though its label flags a tamoxifen interaction. A third option, Lynkuet, is also FDA-approved — we cover it below.
Two quick definitions we use throughout: Vasomotor symptoms (VMS) is the medical name for hot flashes and night sweats. Nonhormonal means the medicine is not estrogen and does not replace estrogen. Both are nonhormonal, both need a prescription, and neither is a controlled substance.
Best for / not for you if…
Veozah may fit you better if:
- ✓Hot flashes or night sweats are your main problem.
- ✓You want a nonhormonal option that is not an antidepressant.
- ✓You can get baseline and follow-up liver blood tests done.
- ✓You don’t take a CYP1A2 inhibitor.
- ✓You don’t have cirrhosis, severe kidney disease, or end-stage kidney disease.
- ✓Insurance or a savings card makes the price realistic for you.
Brisdelle may fit you better if:
- ✓Cost is your biggest concern, and the generic is an option.
- ✓You want a simple oral pill with no drug-specific lab schedule.
- ✓You are not taking tamoxifen.
- ✓You and your clinician are comfortable with SSRI-type risks.
Neither may be your starting point if:
- ›Your main problems are vaginal dryness, painful sex, or urinary symptoms (these need different treatment).
- ›You have unexplained bleeding, active cancer-treatment questions, liver disease symptoms, or possible pregnancy.
- ›You’re not sure whether hormones, a nonhormonal pill, or in-person care is right for you.
Not sure which side of this you fall on?
Use The HRT Index’s Find My HRT Path tool— about 90 seconds, free, and it gives you a personalized starting point you can bring to a consult.
Take the free Find My HRT Path quiz →The HRT Index Brisdelle vs Veozah Decision Matrix
Built from the current FDA prescribing labels, the FDA’s 2024 liver-safety update, manufacturer pricing, and pharmacy price snapshots — with an “ask your clinician if…” column so you walk into a consult already prepared. Not medical advice and does not replace a clinician’s judgment. Last verified: July 2026.
| Decision factor | Brisdelle | Veozah | Ask your clinician if… |
|---|---|---|---|
| Generic name / dose | Paroxetine mesylate 7.5 mg, once daily at bedtime | Fezolinetant 45 mg, once daily | “Am I asking about brand Brisdelle, generic paroxetine, or a different SSRI?” |
| Drug class | SSRI (selective serotonin reuptake inhibitor — an antidepressant type, used here at a low dose) | NK3 receptor antagonist (blocks a brain signal tied to temperature control) | “Does one mechanism fit my other medications better?” |
| FDA approved for | Moderate-to-severe VMS of menopause (2013) | Moderate-to-severe VMS of menopause (2023) | “Are my symptoms actually hot flashes and night sweats?” |
| How well it worked (vs placebo, week 12) | 0.9 and 1.7 fewer hot flashes/day in its two trials | ~2.5 fewer hot flashes/day; the label calls this statistically significant and clinically meaningful | “Given my starting number of hot flashes, what drop would feel meaningful?” |
| How fast | Gradual over weeks | Often noticeable within the first week | “How long should I try it before we decide it’s working?” |
| Boxed warning | Suicidal thoughts/behaviors (an SSRI class warning) | Rare, serious liver injury | “Which of these warnings matters most for me?” |
| Required lab monitoring | None specific to the drug | Liver blood tests before starting, monthly for the first 3 months, then at months 6 and 9 | “Where will I get the liver tests, and who reads the results?” |
| Key interaction | Strong CYP2D6 inhibitor — may lower tamoxifen’s effect | Contraindicated with CYP1A2 inhibitors (e.g., fluvoxamine, mexiletine, cimetidine) | “Do I take tamoxifen or any CYP1A2 inhibitor?” |
| Main contraindications | MAOIs (within 14 days), thioridazine, pimozide, pregnancy | Cirrhosis, severe/end-stage kidney disease, CYP1A2 inhibitors | “Do any of my diagnoses or drugs rule this out?” |
| Common side effects | Headache, fatigue, nausea/vomiting | Belly pain, diarrhea, insomnia, back pain, higher liver enzymes | “Which side effects mean I should stop and call you?” |
| Cash price (30 days) | Brand around $200+; generic roughly $51–$69 with a discount card | Roughly $690–$772; discount cards around $475 (no generic yet) | “What will I actually pay after insurance and any savings card?” |
| Controlled substance? | No | No | — |
Sources: FDA/DailyMed labels for Brisdelle and Veozah; FDA Drug Safety Communication (2024); GoodRx, SingleCare, and Drugs.com price snapshots (verified July 2026). Full source list at the end.
Is Veozah better than Brisdelle?
Here’s where we’ll be straight with you: neither of these pills works as well as hormone therapy, and no trial has crowned one of them the winner. For women who cansafely take estrogen, hormones usually control hot flashes better (The Menopause Society). That’s not us being negative — it’s the reason this comparison exists. Millions of women can’t or won’t take estrogen: breast cancer survivors, women with specific clotting histories, women who have tried hormones and stopped, and women who just prefer not to.
If your only question is “which drug had the stronger hot-flash number in its own FDA trials?”— that’s Veozah. If your real question is “which one fits my budget, my medication list, my liver-test reality, and my risk history?”— you need the full picture below.
What are Brisdelle and Veozah, and how do they work?
How Brisdelle works
Brisdelle contains paroxetine — the same active ingredient as Paxil — but at a much lower 7.5 mg dose. It’s taken once at bedtime. It was FDA-approved in 2013 as the first nonhormonal drug for hot flashes. One honest quirk: the label itself says the exact way it eases hot flashes isn’t fully known. At this dose, it isn’t known to cause the weight gain that higher-dose paroxetine can.
How Veozah works
Veozah contains fezolinetant and works completely differently. When estrogen drops in menopause, certain brain cells that help regulate body temperature get overactive — part of what triggers a hot flash. Veozah blocks the NK3 receptor those cells use, helping settle the “thermostat” back down. FDA-approved in May 2023, the first drug in its class. Once-daily, with or without food.
That difference in howthey work drives the whole decision. Because Brisdelle is an SSRI, it comes with SSRI-type warnings and the tamoxifen interaction. Because Veozah works on a brain-temperature pathway instead, it skips those — but brings its own liver monitoring and a much higher price. Neither one is built to fix vaginal dryness, painful sex, urinary symptoms, bone loss, or mood problems as the main issue.
Which one worked better in clinical studies?
| Label data point | Brisdelle | Veozah |
|---|---|---|
| Trials | Two Phase 3, randomized, placebo-controlled | Two Phase 3, randomized, placebo-controlled (first 12 weeks) |
| Starting hot flashes | ~7–10 moderate-to-severe per day | At least ~7 moderate-to-severe per day |
| Extra reduction vs placebo (week 12) | 0.9/day in one study; 1.7/day in the other | ~2.5–2.6/day in each study |
| What the label says | A modest but statistically significant benefit; some women still felt a meaningful difference | Statistically significant and clinically meaningful, defined as ≥2 fewer hot flashes over 24 hours vs placebo |
| Honest read | A small average benefit that helps some women | A larger average benefit — but paired with liver monitoring and a much higher price |
Two things to hold onto here. First, hot-flash trials have a bigplacebo effect — a lot of women improve on a sugar pill — so the drug’s true added benefit is often smaller than headlines suggest. Second: average benefit isn’t your benefit.A side effect you can’t tolerate, a drug interaction, or a price you can’t afford matters far more than a half-a-hot-flash difference on a chart.
We won’t tell you Veozah is “clinically proven” to be the better drug, because no head-to-head trial exists to say that. What we can show is what each drug’s own label reports — which is exactly what we’ve done above.
The safety trade-off: liver warning vs. SSRI warning
Veozah’s liver warning — what matters
In December 2024, the FDA added a boxed warning after a reported case of serious liver injury. The label now requires liver blood tests before you start, then monthly for the first three months, and again at months 6 and 9.Across three trials, liver-enzyme rises above 3× normal happened in 2.3%of women on Veozah versus 0.9% on placebo — and most were symptom-free. This monitoring is mandatory, not optional.
Stop and call your clinician if you notice: new tiredness, loss of appetite, nausea, vomiting, itching, yellow skin or eyes, pale stools, dark urine, or belly pain.
Brisdelle’s SSRI warnings
As a low-dose SSRI, Brisdelle carries the class boxed warning about suicidal thoughts and behaviors (even though it isn’t approved to treat depression). Other SSRI cautions: serotonin syndrome, abnormal bleeding, low sodium, and discontinuation symptoms if stopped suddenly. Not for use with MAOIs within 14 days, thioridazine, or pimozide. Contraindicated in pregnancy.
Veozah is also contraindicated with CYP1A2 inhibitors (cimetidine, fluvoxamine, mexiletine) and in patients with cirrhosis or severe/end-stage kidney disease.
Quick “does this rule one out for me?” guide
| If this is you… | Brisdelle concern | Veozah concern |
|---|---|---|
| You take tamoxifen | May lower tamoxifen’s effect (see next section) | No paroxetine/CYP2D6 interaction — but check its own cautions |
| You take a CYP1A2 inhibitor | Not the main issue | Contraindicated — do not combine |
| You have cirrhosis | Not the specific issue | Contraindicated |
| You can’t do routine blood tests | Simpler on monitoring | Requires liver labs |
| You want to avoid antidepressant-type effects | May not fit | Not an SSRI — may fit if labs are doable |
| You’re pregnant or could be | Contraindicated | Discuss first; menopause VMS context usually doesn’t apply |
Can you take Brisdelle with tamoxifen? The catch after breast cancer
Tamoxifen is a “prodrug” — your body has to convert it into endoxifen to do its job. Paroxetine gets in the way of that conversion. In a study cited in the FDA’s own review of the Brisdelle approval, paroxetine 10 mg a day for four weeks dropped endoxifen levels by 64% (NEJM).
The honest nuance
Whether this actually changes breast cancer outcomes (relapse or survival) is not settled. Some studies found a signal of harm; a very large study did not. The label reflects that uncertainty — telling clinicians to weigh Brisdelle’s benefit against the possibledrop in tamoxifen’s effect. In practice, most oncologists and menopause specialists play it safe and steer tamoxifen users away from paroxetine.
If you take tamoxifen and you’re choosing between these two, Veozah is the one withoutthis interaction — though you’d still weigh its liver labs, CYP1A2 cautions, and cost. Other nonhormonal options that don’t touch CYP2D6 — like venlafaxine (an SNRI) — are also worth raising with your clinician.
What side effects are most common?
Brisdelle side effects
Headache, fatigue, and nausea or vomiting. Nausea tends to show up in the first few weeks and fatigue in the first week; both usually fade with time. Don’t stop it suddenly— SSRIs can cause discontinuation symptoms, so any change should go through your clinician.
Veozah side effects
Belly pain, diarrhea, insomnia, back pain, and elevated liver enzymes. The standout isn’t a “feel-it” side effect — it’s the liver-enzyme rise, which is why the blood tests exist. Treat those labs as central to using the drug, not as background paperwork.
What Brisdelle users report
Real public feedback from Drugs.com, source named. Individual experiences, not proof of safety or efficacy.
On Drugs.com, Brisdelle holds a 6.4 out of 10 average across 37 reviews for hot flashes — 54% reported a positive experience, 27% negative. One reviewer described going from waking multiple times a night drenched to zero night sweats after starting. Another said it worked on her hot flashes but she stopped over side effects like insomnia and restlessness.
Results vary widely from person to person. These are individual experiences only.
How much does Brisdelle vs Veozah cost?
| Cost item | Brisdelle / paroxetine | Veozah |
|---|---|---|
| Generic available? | Yes — generic paroxetine mesylate 7.5 mg | Not yet; patents listed into 2034, though timing can change |
| Cash price (30 days) | Brand around $200+; generic roughly $51–$69 with a discount card | Roughly $690–$772; discount cards around $474–$485; manufacturer list price about $550 |
| Manufacturer savings | Generic is already low-cost | Commercial insurance: $0 first month, as little as $30 per refill (annual cap ~$4,000) |
| Who can’t use the savings card | — | Medicare, Medicaid, TRICARE, and VA patients don’t qualify |
| Typical insurance friction | Usually covered (generic) | Coverage varies; often needs prior authorization or step therapy |
Prices verified July 2026 via GoodRx, SingleCare, Drugs.com, and Astellas.
The cost decision rule is simple. If you’re paying cash and the generic is appropriate, Brisdelle is almost always the lower-friction option. If Veozah is the better clinical fit, your real cost depends heavily on insurance, prior authorization, and whether you qualify for the savings card. Either way, the smartest move is to find out what you’d actually pay before you commit.
Get evaluated and see your covered cost in one visit
You can’t get either drug without a prescriber, and Veozah’s price swings wildly depending on coverage. Midi Healthis a menopause-focused telehealth practice that prescribes FDA-approved nonhormonal treatments for hot flashes, available in all 50 states and in-network with most PPO plans — so you can get evaluated and see your covered cost in one visit.
One honest limitation: Midi doesn’t accept Medicaid or Medi-Cal, and it isn’t covered by Medicare. If that’s your coverage, a cash-pay service or your own OB/GYN is the better route.
| Claim about Midi | Source type | Verified |
|---|---|---|
| Available in all 50 states | Provider-stated (Midi Health website) | July 2026 |
| In-network with most PPO plans | Provider-stated (Midi Health website) | July 2026 |
| Prescribes FDA-approved nonhormonal hot-flash options | Provider-stated (Midi Health website) | July 2026 |
| Does not treat Medicaid/Medi-Cal; not covered by Medicare | Provider-stated (Midi Health website) | July 2026 |
| The exact drug prescribed for you | Confirm at intake — depends on your state, plan, and history | — |
Disclosure: The HRT Index may earn a commission if you book through the link above, at no added cost to you. We don’t rank providers by payout — we route by fit first.
What changes with insurance, Medicare, Medicaid, or a savings card?
| Your coverage | Best move |
|---|---|
| Commercial insurance | Check the Veozah savings card; expect possible prior authorization or step therapy |
| Medicare | No manufacturer savings card; check your Part D plan’s formulary and tier |
| Medicaid / Medi-Cal | Midi isn’t available to you; check your plan’s coverage, or an in-person or cash route |
| Paying cash | Generic paroxetine is usually the lower-friction option; Veozah’s coupon price is still high |
Questions worth asking your plan before you fill anything:
- ›Is this drug on my formulary?
- ›Is prior authorization required?
- ›Does my prescriber need to document that I tried something cheaper first?
- ›Does the savings card work with my plan type?
- ›What will the first fill and the refills cost?
- ›What happens if coverage is denied?
Who should ask a clinician about Brisdelle first?
Brisdelle fits the woman thinking:
“I need a nonhormonal option, cost matters, I’m not on tamoxifen, and I’d rather skip Veozah’s lab schedule.”
Bring these questions to your consult:
- ›Is Brisdelle different from the paroxetine dose used for depression?
- ›Would generic paroxetine be appropriate, or do I need the brand?
- ›Do any of my medications create bleeding, seizure, or serotonin concerns?
- ›Am I on tamoxifen, or could I be in the future?
- ›What side effects should make me call you?
- ›How would we stop it safely if I don’t tolerate it?
Who should ask a clinician about Veozah first?
Veozah fits the woman thinking:
“I want to avoid estrogen or can’t take it, I don’t want an SSRI, my main issue is hot flashes or night sweats, and I can handle the blood tests and the cost.”
Bring these questions to your consult:
- ›What liver labs do I need before starting?
- ›Where do I get the monthly labs for the first three months?
- ›Who reviews the results if a number comes back off?
- ›Which symptoms mean I should stop and call you?
- ›Do any of my medications inhibit CYP1A2?
- ›What will I pay after insurance or the savings card?
- ›What’s the backup plan if it’s denied or unaffordable?
When is neither Brisdelle nor Veozah the right starting point?
Look beyond these two drugs if your bigger issues are vaginal dryness, painful sex, recurrent urinary symptoms, unexplained bleeding, new pelvic pain, a mood disorder as the primary concern, or sleep problems that aren’t driven by hot flashes. Those point to different treatments entirely.
And it’s worth saying plainly: for women who can safely take it, hormone therapy is the most effective treatment for hot flashes and night sweats(The Menopause Society). It also treats vaginal and urinary symptoms that these pills don’t. If you’ve been avoiding estrogen out of fear rather than a real medical reason, it’s worth asking whether you’re actually a candidate.
Some situations really belong with an in-person clinician first:
- ›Active cancer treatment or complex oncology history
- ›Liver disease symptoms
- ›Severe kidney disease
- ›A complex psychiatric medication regimen
- ›Unexplained bleeding
- ›Possible pregnancy
- ›Symptoms severe enough to need urgent care
What about Lynkuet, hormone therapy, and other options?
Three FDA-approved nonhormonal pills at a glance
| Pill | Class | Dosing | Liver monitoring | Notable point |
|---|---|---|---|---|
| Brisdelle | SSRI (paroxetine) | Once daily at bedtime | None specific to the drug | Cheapest; tamoxifen/CYP2D6 caution |
| Veozah | NK3 antagonist | Once daily | Before start, monthly ×3, then months 6 & 9 | Larger label efficacy signal; boxed liver warning |
| Lynkuet | Dual NK1/NK3 antagonist | Once daily at bedtime | Baseline and again at 3 months | Newest (Oct 2025); no boxed warning; pregnancy contraindication |
- ›Lynkuet (elinzanetant) is the first dual NK1/NK3 receptor blocker, approved by the FDA in October 2025. It has a lighter liver-check schedule than Veozah and did not receive a boxed warning. See our Lynkuet vs Veozah comparison and Lynkuet vs paroxetine for the full picture.
- ›Hormone therapy (estrogen, with progesterone if you have a uterus) is the most effective treatment for hot flashes for appropriate candidates, and it treats vaginal and urinary symptoms too.
- ›Off-label nonhormonal options— venlafaxine, gabapentin, oxybutynin — are used in specific cases, especially when tamoxifen or other factors make Brisdelle or Veozah a poor fit.
Can you switch from Brisdelle to Veozah, or take them together?
Don’t switch or combine on your own.
Brisdelle can cause discontinuation symptoms if stopped abruptly, and Veozah requires baseline liver labs and a medication review before you start. Any switch should go through a clinician.
If your first option isn’t working, the reason matters — no benefit, side effects, cost, or coverage all lead to different next steps. You may need to taper off Brisdelle gradually. You’ll need baseline liver tests before starting Veozah, plus a check for CYP1A2 interactions. And you’ll want to know how long to give the new option before judging it.
Questions to ask before switching:Why did the first one fail? Do I need to taper? Do I need baseline labs? When should I expect improvement? What’s the stop rule?
How The HRT Index verified this comparison
✓ What we actually verified (July 2026)
- ›FDA/DailyMed label details for Brisdelle and Veozah
- ›Approved uses, doses, and drug classes
- ›Boxed warnings, contraindications, and key interactions (tamoxifen/CYP2D6 for Brisdelle; CYP1A2 for Veozah)
- ›Veozah’s liver-test schedule and the FDA’s 2024 boxed-warning update
- ›Placebo-adjusted hot-flash reduction numbers from each drug’s trials, and the FDA label’s “clinically meaningful” definition for Veozah
- ›Current cash prices and savings-program terms
- ›That Lynkuet (elinzanetant) is FDA-approved (Oct 2025) as a third nonhormonal option
- ›Midi Health’s stated state availability, PPO participation, nonhormonal prescribing, and Medicaid/Medicare limits
⚠️ What we did not verify
- ›Any head-to-head trial proving one drug is better for every woman (none exists)
- ›Your personal insurance coverage or your pharmacy’s final price
- ›Whether either drug is right for your specific medical history
- ›Whether a specific provider can prescribe the exact drug you want in your state
Frequently asked questions
- Is Veozah better than Brisdelle?
- Veozah showed larger placebo-adjusted hot-flash reductions in its own trials — about 2.5 fewer per day — than Brisdelle did in its trials, which showed 0.9 to 1.7 fewer per day at week 12. Veozah’s label calls its reduction statistically significant and clinically meaningful. But there is no head-to-head study, and cost, liver monitoring, drug interactions, and your health history can all change which one fits you best.
- Is Brisdelle the same as Paxil?
- Both contain paroxetine, but Brisdelle is a low 7.5 mg dose approved specifically for menopause hot flashes, while Paxil is a higher-dose paroxetine used for depression and anxiety. Do not switch between paroxetine products on your own.
- Is Veozah a hormone?
- No. Veozah is not estrogen and is not hormone therapy. It is fezolinetant, a nonhormonal NK3 receptor antagonist that works on a brain pathway tied to body temperature.
- Does Veozah require liver tests?
- Yes. The Veozah label requires liver blood tests before you start, monthly for the first three months, and again at months 6 and 9. The FDA also added a boxed warning in 2024 about rare but serious liver injury.
- Can I take Brisdelle with tamoxifen?
- Brisdelle’s label advises weighing its benefit against a possible drop in tamoxifen’s effectiveness and considering avoiding the combination. Paroxetine can lower blood levels of tamoxifen’s active form (endoxifen) by about 64%, though whether that changes cancer outcomes is not settled. If you take tamoxifen, talk to your oncology or menopause clinician before choosing Brisdelle — Veozah or a non-interacting option is often preferred.
- Which is cheaper, Brisdelle or Veozah?
- Brisdelle, usually by a wide margin. Generic paroxetine ran about $51–$69 a month with a discount card at our last check, while Veozah ran about $690–$772 a month cash. With commercial insurance, a Veozah savings card can lower that significantly.
- Which works faster, Brisdelle or Veozah?
- Veozah often shows improvement within the first week in trials, while Brisdelle tends to work more gradually. Individual timing varies, so ask your clinician how long to give it before deciding.
- What about Lynkuet — should I consider it too?
- Lynkuet (elinzanetant) is a newer FDA-approved nonhormonal pill for hot flashes, approved in October 2025. It is a dual NK1/NK3 receptor blocker taken at bedtime, with a lighter liver-check schedule than Veozah and no boxed warning. If you are comparing nonhormonal options broadly, it is worth raising with your clinician.
- Can I use either if I can’t take estrogen?
- Possibly — both are nonhormonal. But “nonhormonal” does not automatically mean appropriate for you. Your clinician still needs to review your history, medications, symptoms, and liver and kidney health, and decide whether online or in-person care is right.
- Are natural remedies safer than Brisdelle or Veozah?
- Not automatically. “Natural” does not mean proven, safer, or free of interactions. If your symptoms are severe or you take other medications, discuss supplements and lifestyle approaches with a clinician rather than assuming they are risk-free.
Still deciding?
There’s no single right answer to Brisdelle vs Veozah — there’s a right answer for you, and it hinges on tamoxifen, your budget, and whether liver monitoring is realistic. Sort those out before your consult and you’ll walk in ready to decide instead of starting from scratch.
Also compare: Veozah vs paroxetine · Lynkuet vs Veozah · Lynkuet vs paroxetine · All nonhormonal options
Still not sure which HRT path is right for you? Take our free Find My HRT Path quiz — about 90 seconds, free, and it gives you a personalized action plan.
Start Find My HRT Path →Sources
- 1.U.S. Food & Drug Administration — Drug Safety Communication: boxed warning for serious liver injury with Veozah (fezolinetant), 2024.
- 2.U.S. Food & Drug Administration — Drug Trials Snapshots: Veozah (clinically meaningful reduction defined as ≥2 hot flashes over 24 hours).
- 3.DailyMed / FDA prescribing label — VEOZAH (fezolinetant): indications, contraindications, warnings, liver-test schedule, hepatotoxicity data.
- 4.DailyMed / FDA prescribing label — BRISDELLE (paroxetine) 7.5 mg: indications, warnings, tamoxifen/CYP2D6 language, trial data.
- 5.DailyMed / FDA prescribing label and Bayer press release — LYNKUET (elinzanetant): approval (October 2025), indication, dosing, liver monitoring.
- 6.New England Journal of Medicine — analysis of the FDA approval of Brisdelle (placebo-adjusted efficacy; endoxifen data).
- 7.The Menopause Society — hormone therapy and nonhormone therapy position statements.
- 8.GoodRx, SingleCare, Drugs.com — pricing snapshots for Brisdelle/paroxetine and Veozah (verified July 2026).
- 9.Astellas Pharma — Veozah savings program terms.
- 10.Midi Health — nonhormonal prescribing scope, state availability, and insurance participation (verified July 2026).
- 11.Drugs.com — public user reviews for Brisdelle (hot flashes).
The HRT Index is an independent decision resource for online menopause and HRT care for women. This page is educational research and is not medical advice and not medically reviewed by a clinician. FDA-approved and compounded medications are always kept distinct. Always talk with a licensed clinician before starting, stopping, or changing any medication. Prices and drug labels change — see the “Last verified” date above.
Affiliate disclosure: The HRT Index is reader-supported. If you book with a provider through our links, we may earn a commission at no additional cost to you. This never affects our medical facts, our verification, or which option we say fits you.
Last verified: July 2026. Pricing, insurance coverage, savings-card terms, FDA labeling, and provider availability can change. The HRT Index re-checks top medication and provider pages monthly under The HRT Index Verification Standard.